Video

Incorporating Esketamine into Practice for Treatment-Resistant Depression

Author(s):

Steven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP

Additional variables that require consideration if treating appropriate patients with treatment-resistant depression with intranasal esketamine within certified treatment facilities.

Related Videos
Depression Screening: Challenges and Solutions at the Primary Care Level
Etienne Sibille, PhD: Innovations in Cognitive Pathology
Manish Jha, MD: Treatment Options for Treatment-Resistant Depression
Sunny Rai, PhD: “I” Language Markers Do Not Detect Depression in Black Individuals
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD
Related Content
Credit: Adobe Stock / Pormezz
December 16th 2024

High Prevalence of RLS Found in Patients with MDD, Migraine, Anxiety

Chelsie Derman
Medical Ethics Unpacked:
November 22nd 2024

Medical Ethics Unpacked: Ethical Foundations and Background of Euthanasia & Medically-Assisted Suicide

Steven Levine, MD Dominic Sisti, PhD
Where is the Mental Health Crisis Heading in 2025? Hear from Experts | Credit: HCPLive
December 13th 2024

Where is the Mental Health Crisis Heading in 2025? Hear from Experts

Chelsie Derman
Mark Heyman, PhD | Credit: LinkedIn
June 25th 2023

Diabetes Dialogue: Managing & Addressing Mental Health Needs in Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Maria E. Garcia, MD I University of California, San Francisco
December 10th 2024

Study Identifies Depression Treatment Gaps by Ethnicity, Age, Suicidal Risk

Chelsie Derman
Anthony Back, MD I UW Medicine
December 6th 2024

Psilocybin Therapy Eases Clinicians' Depression Post-COVID Frontline Work

Chelsie Derman
© 2024 MJH Life Sciences

All rights reserved.